{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:24:40Z","timestamp":1779171880573,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:00:00Z","timestamp":1610236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:00:00Z","timestamp":1610236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13555-020-00477-6","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T12:02:45Z","timestamp":1611057765000},"page":"433-447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan"],"prefix":"10.1007","volume":"11","author":[{"given":"Jake","family":"Macey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie V. J.","family":"Aldhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russel T.","family":"Burge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3187-331X","authenticated-orcid":false,"given":"Emily","family":"Edson-Heredia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill S.","family":"McCollam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoe","family":"Torisu-Itakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,10]]},"reference":[{"key":"477_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2018.12.001","volume":"98","author":"T Simakou","year":"2019","unstructured":"Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: a multifactorial autoimmune condition. J Autoimmun. 2019;98:74\u201385.","journal-title":"J Autoimmun"},{"key":"477_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82:675\u201382.","journal-title":"J Am Acad Dermatol"},{"key":"477_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1346-8138.2011.01209.x","volume":"38","author":"M Furue","year":"2011","unstructured":"Furue M, Yamazaki S, Jimbow K, et al. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. J Dermatol. 2011;38:310\u201320.","journal-title":"J Dermatol"},{"issue":"806","key":"477_CR4","first-page":"12.e3","volume":"75","author":"LY Liu","year":"2016","unstructured":"Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. 2016;75:806\u201312.e3.","journal-title":"J Am Acad Dermatol"},{"key":"477_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"LY Liu","year":"2018","unstructured":"Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79:556\u20138.e1.","journal-title":"J Am Acad Dermatol"},{"key":"477_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjd.14497","volume":"175","author":"F Rencz","year":"2016","unstructured":"Rencz F, Gulacsi L, Pentek M, Wikonkal N, Baji P, Brodszky V. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol. 2016;175:561\u201371.","journal-title":"Br J Dermatol"},{"key":"477_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijwd.2017.07.001","volume":"4","author":"R Abedini","year":"2018","unstructured":"Abedini R, Hallaji Z, Lajevardi V, Nasimi M, Karimi Khaledi M, Tohidinik HR. Quality of life in mild and severe alopecia areata patients. Int J Womens Dermatol. 2018;4:91\u20134.","journal-title":"Int J Womens Dermatol"},{"key":"477_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijwd.2017.11.007","volume":"4","author":"DS Davis","year":"2018","unstructured":"Davis DS, Callender VD. Review of quality of life studies in women with alopecia. Int J Womens Dermatol. 2018;4:18\u201322.","journal-title":"Int J Womens Dermatol"},{"key":"477_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","volume":"4","author":"NVJ Aldhouse","year":"2020","unstructured":"Aldhouse NVJ, Kitchen H, Knight S, et al. \u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed:\u201d a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;4:76.","journal-title":"J Patient Rep Outcomes"},{"key":"477_CR10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/1346-8138.14986","volume":"46","author":"H Park","year":"2019","unstructured":"Park H, Yu D-A, Kwon O. Janus kinase inhibitors: an innovative treatment for alopecia areata. J Dermatol. 2019;46:724\u201330.","journal-title":"J Dermatol"},{"key":"477_CR11","first-page":"2741","volume":"127","author":"R Tsuboi","year":"2017","unstructured":"Tsuboi R, Itami S, Manabe M, et al. Japanese Dermatological Association guidelines for treatment of alopecia areata 2017. Jpn J Dermatol. 2017;127:2741\u201362 ([In Japanese]).","journal-title":"Jpn J Dermatol"},{"key":"477_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40257-014-0086-4","volume":"15","author":"M Hordinsky","year":"2014","unstructured":"Hordinsky M, Donati A. Alopecia areata: an evidence-based treatment update. Am J Clin Dermatol. 2014;15:231\u201346.","journal-title":"Am J Clin Dermatol"},{"key":"477_CR13","unstructured":"ClinicalTrials.gov. A study of baricitinib (LY30009104) in adults with severe or very severe alopecia areata (BRAVE-AA2). National Library of Medicine (US); 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03899259. Accessed 6 Oct 2020."},{"key":"477_CR14","unstructured":"ClinicalTrials.gov. PF-06651600 for the treatment of alopecia areata (ALLEGRO-2b\/3). National Library of Medicine (US); 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03732807. Accessed 6 Oct 2020."},{"key":"477_CR15","unstructured":"ClinicalTrials.gov. A study of baricitinib (LY3009104) in participants with severe or very severe alopecia areata (BRAVE-AA1). National Library of Medicine (US); 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03570749. Accessed 6 Oct 2020."},{"key":"477_CR16","unstructured":"ClinicalTrials.gov. Long-term PF-06651600 for the treatment of alopecia areata (ALLEGRO-LT). National Library of Medicine (US); 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04006457. Accessed 6 Oct 2020."},{"key":"477_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20:1043\u20139.","journal-title":"Nat Med"},{"key":"477_CR18","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1:e89790.","journal-title":"JCI Insight"},{"key":"477_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","volume":"76","author":"BG Craiglow","year":"2017","unstructured":"Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76:29\u201332.","journal-title":"J Am Acad Dermatol"},{"key":"477_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76:22\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"477_CR21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","volume":"138","author":"A Jabbari","year":"2018","unstructured":"Jabbari A, Sansaricq F, Cerise J, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Investig Dermatol. 2018;138:1539\u201345.","journal-title":"J Investig Dermatol"},{"key":"477_CR22","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.jisp.2017.10.003","volume":"19","author":"LY Liu","year":"2018","unstructured":"Liu LY, King BA. Tofacitinib for the treatment of severe alopecia areata in adults and adolescents. J Investig Dermatol Symp Proc. 2018;19:S18\u201320.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"477_CR23","unstructured":"Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed 6 Oct 2020."},{"key":"477_CR24","unstructured":"Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input guidance for industry, Food and Drug Administration staff, and other stakeholders. 2018. https:\/\/www.fda.gov\/media\/139088\/download. Accessed 6 Oct 2020."},{"key":"477_CR25","unstructured":"Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients guidance for industry, Food and Drug Administration staff, and other stakeholders. 2019. https:\/\/www.fda.gov\/media\/131230\/download. Accessed 6 Oct 2020."},{"key":"477_CR26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bjd.18883","volume":"183","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, Kitchen H, Knight S, et al. The Alopecia Areata Investigator\u2019s Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020;183:702\u20139.","journal-title":"Br J Dermatol"},{"key":"477_CR27","doi-asserted-by":"crossref","unstructured":"Wyrwich KW, Kitchen H, Knight S, et al. Development of the Scalp Hair Assessment PRO\u2122 measure for alopecia areata. Br J Dermatol. 2020;183(6):1065\u201372.","DOI":"10.1111\/bjd.19024"},{"key":"477_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines\u2014part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51:440\u20137.","journal-title":"J Am Acad Dermatol."},{"key":"477_CR29","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40257-020-00545-9","volume":"21","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, Kitchen H, Knight S, et al. Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata. Am J Clin Dermatol. 2020;21:725\u201332.","journal-title":"Am J Clin Dermatol"},{"key":"477_CR30","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jisp.2020.05.006","volume":"20","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, Kitchen H, Knight S, et al. The role of patients in alopecia areata endpoint development: understanding physical signs and symptoms. J Investig Dermatol Symp Proc. 2020;20:S71\u20137.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"477_CR31","doi-asserted-by":"crossref","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2014assessing respondent understanding. Value Health. 2011;14:978\u201388.","DOI":"10.1016\/j.jval.2011.06.013"},{"key":"477_CR32","unstructured":"Willis GB. Cognitive interviewing: a tool for improving questionnaire design. New York: Sage; 2004."},{"key":"477_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"477_CR34","volume-title":"Applied thematic analysis","author":"G Guest","year":"2011","unstructured":"Guest G, MacQueen KM, Namey EE. Applied thematic analysis. New York: Sage; 2011."},{"key":"477_CR35","volume-title":"Qualitative research practice: a guide for social science students and researchers","author":"J Ritchie","year":"2013","unstructured":"Ritchie J, Lewis J, Nicholls CM, Ormston R. Qualitative research practice: a guide for social science students and researchers. New York: Sage; 2013."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00477-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13555-020-00477-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00477-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T07:20:04Z","timestamp":1617348004000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-020-00477-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,10]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["477"],"URL":"https:\/\/doi.org\/10.1007\/s13555-020-00477-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,10]]},"assertion":[{"value":"26 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}